CA Startup w/Diagnostic Tech Seeks Equity 2 Penetrate $200T Mrkts.

Opportunity Snapshot

Investment Opportunity

We have pioneered & patntd new, green, Med Diagnostic screening tools.1200 tests.99.9% accuracy;100% safe;0 direct competitors.Offers Better,cheaper,& faster diagnosis.

We solve PROBLEMS & fill unmet NEEDS in medicine, through next-gen medical device technologies. Our first product is called the “Multi-Organ Diagnostic System” (hereafter referred to as MODS) a non-invasive & non-stimulatory diagnostic screening tool, which instantly pinpoints the degree of different organ pathology/illness; advises the user of organ condition; & may eventually name the illness prior to clinical symptomology. Per our Executive Summary (ES), MODS is better, faster & cheaper than current imaging technologies (X-Ray, MRI, PET, CT, SPECT, Ultrasound, & Nuclear Imaging). Present diagnosis technologies DO NOT give an instant & accurate picture of overall organ health; are OPEN to physician error, & many organs simply CANNOT be medically assessed in this manner. Our invention, arose from our pioneering work in electro-medicine w/ bio-potential measurements, & finding direct correlations to organ health diagnosis. Similar in some ways to the EKG, we measure energy not introduced into, but “given off” by the body, & utilize software to measure bilateral asymmetry of the signals, arriving at quick, reliable, easy to read, color-coded (green, yellow, & red), health assessment of 12 organs. Per our ES, The Diagnostic Imaging Market for Traditional X-ray, CT, PET, MRI, Ultrasound, & Nuclear Medicine is enormous: $ 9.6 B/yr US; & $ 23.4 B/yr. worldwide. With 491M Radiologic exams & 23M Nuclear medicine exams annually in the US (a $1.3 trillion US annual billing stream), we believe MODS will be used in a growing %tage of Diagnostic Radiology exams; both capturing a portion of, & exhibiting strong growth in tandem w/ these above figures. US target customers consist of Health Providers (i.e. Hospitals & Relevant Targeted Medical Practitioners); Medical Insurance Providers/Payors; and EMT’s resulting in 664M total potential US customers: a $200 Trillion US market. Revenue will be generated through the sales of MODS devices w/ a $75k retail price planned distributed by an established corporate partner at wholesale or lease. The hospital or physician will charge patients $150-$300 for each diagnosis. With est. manufacturing cost of approx. $9k/unit, our GP is a healthy 83.3%. Using MODS 3x a day would generate $160+k a year in charges for the user/care provider, paying for itself in less than 6 mos! Project Justification is shown in the ES and accompanying doc “Proof of New Tech. NEED-Our MODS device vs existing diagnostic imaging technologies.” With trillions of dollars at stake, & ongoing growth use in medicine, current diagnostics are FAILING US, costing us billions, & one of the largest contributors of rising US per capita healthcare costs. Our breakthrough technology is needed to bring order & reduce costs all around. Presently, we’re a start up, w/ approximately $5M dollars invested from the founding team. We have a proof-of-concept prototype, & conducted over 1,200 successful trials LA Hospitals w/ 99.9 % accuracy, and have patents on all devices w/addt’l patents to be filed and granted. Next milestone requires $6.3M to get to a production prototype for FDA testing. We seek total cash infusions of $26.7M in exchange for equity position, to open ops, continue prototypes & fund Class III PMA FDA approval, & commercialization, based on CF projections. Breakeven projected in yr 4: selling just 681 units! Anticipated ROI is 1289% in 5 yrs (Net Profit 344,150,823/26,700,000 capital invst) *100)

Competitive Advantage

Five to six dominant players are recognized as “indirect competitors” offering a buffet of many differing modalities of traditional & advanced imaging equipment, with America as their largest market. They represent & control the present & future R&D in this field, & are otherwise unchallenged from outsiders.

Review of the portfolios of 70 of the largest early-stage VC’s specializing in medical devices & healthcare demonstrate no investments in diagnostic imaging, other than: one with a more portable ultrasound, & another with an improved cardiac-imaging tech/software.

The top 3 Big-Tech leaders in Imaging are: GE Healthcare (UK), Philips (The Netherlands), & Siemens (Germany); with subsequent competitors Toshiba (Japan), Hitachi (Japan), & Hologic (U.S.) rapidly gaining presence. The current trend of merging of modalities such as PET/CT, SPECT/CT, & MRI/PET enables them to potentially provide a full gamut of imaging scans through the same unit, & at the same time.
Our particular innovation, is quite a significant step forward for diagnostic imaging, for there is no such comparable product. It addresses a clear need, offers new unparalleled benefits, fits a new niche, & thus would be relatively unchallenged, as the sole representative of its kind.

We have significant cost advantages over the million+ dollar machines of our indirect competitors, many of which require specialized rooms, & quite significant costs of energy, cooling, & on-going maintenance. Our sales will be to established corporate distribution partners for $53,000 (incl. initial supply of customer disposable electrodes/unit) & ultimately re-sold to targeted end medical providers at a $75k retail price (a 30% mark-up), or made available through lease. Aeon’s GP is a healthy 83% or approx. $44k per sale.
The end user, hospital or physician, is envisioned to charge patients $150-$300 for the diagnosis scan. Using MODS 3x a day (at $150/scan) would generate $160k+ a year in charges for the user/care provider, with the device paying for itself in less than a half year! This results in quite a smart purchase, with comparatively very low acquisition cost, & lower operative energy costs per patient screening, & offers a new profit area as well as a more mobile diagnostic.
While marketing plans are included in the ES, they include active publishings in peer-reviewed medical journals, attending key trade shows, & seeking publicity through news & television shows. In addition, is it contemplated, in view of our low manufacturing costs that some universities & hospitals will be granted free evaluation models to test & utilize for a specified period of time, in exchange for written articles or other endorsements, or approvals, etc.

Rationale for the deal

Additional information available upon sufficient interest and investor capability to fund.

Use of financing

Additional information available upon sufficient interest and investor capability to fund.

Opportunity for the investor

Additional information available upon sufficient interest and investor capability to fund.

Looking for similar investment opportunities